Golimumab, Centocor’s next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also being studied as an intravenous (IV) infusion therapy.
Jerome Boscia, senior vice president, clinical R&D, Centocor, said: “This submission marks a major milestone in the clinical development program of golimumab, and we look forward to working with the FDA to bring golimumab to market.”